慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2025.03.005

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)合并代谢相关脂肪性肝病(MAFLD)患者外周血单个核细胞(PBMC)半乳糖凝集素(Galectin)-3和Galectin-9水平变化及其临床意义。方法 2021年1月～2024年2月河北大学附属医院收治的CHB合并MAFLD患者138例和CHB患者95例,分离外周血PBMCs,采用实时荧光定量PCR法检测PBMC Galectin-3 mRNA和Galectin-9 mRNA水平。应用多因素非条件Logistic回归分析影响因素,应用受试者工作特征曲线(ROC)分析PBMC Galectin-3 mRNA和Galectin-9 mRNA水平诊断CHB合并MAFLD的效能。结果 CHB合并MAFLD组PBMC Galectin-3 mRNA和Galectin-9 mRNA水平分别为(1.6±0.3)和(1.4±0.2),均显著高于CHB组【分别为(1.3±0.1)和(1.2±0.1),P＜0.05】;多因素分析显示体质指数、高血压病、2型糖尿病、高脂血症、HOMA-IR、Galectin-3 mRNA和Galectin-9 mRNA水平均是CHB合并MAFLD的独立危险因素(P均＜0.05);PBMC Galectin-3 mRNA和Galectin-9 mRNA联合诊断CHB合并MAFLD的曲线下面积(AUC)为0.888,显著大于Galectin-3 mRNA和Galectin-9 mRNA水平单独诊断的0.785和0.791(P＜0.05)。结论 CHB合并MAFLD患者PBMC Galectin-3 mRNA和Galectin-9 mRNA水平异常升高,对诊断CHB合并MAFLD有帮助。

Abstract: Objective The aim of this study was to investigate changes of peripheral blood mononuclear cell (PBMC) galectin-3 and galectin-9 in patients with chronic hepatitis B (CHB) and concomitant metabolism-related fatty liver disease(MAFLD). Methods 138 CHB patients with MAFLD and 95 CHB patients were admitted to Affiliated Hospital, Hebei University between January 2021 and February 2024, and PBMCs were isolated and galectin-3 messenger ribonucleic acid (mRNA) and galectin-9 mRNA was detected by real-time fluorescence quantitative PCR. The influencing factors were determined by multivariate unconditional Logistic regression analysis, and the diagnostic performance of galectin-3 mRNA and galectin-9 mRNA for CHB with MAFLD was analyzed by receiver operating characteristic curve (ROC). Results Galectin-3 mRNA and galectin-9 mRNA in PBMCs in CHB and MAFLD group were (1.6±0.3) and (1.4±0.2), both significantly higher than in CHB group [(1.3±0.1) and (1.2±0.1), respectively, P＜0.05]; Logistic analysis showed that body mass index, hypertension, type 2 diabetes, hyperlipidemia, HOMA-IR, galectin-3 mRNA and galectin-9 mRNA loads were all the independent risk factors for CHB patients having MAFLD (P<0.05); the area under the curve (AUC) for PBMC galectin-3 mRNA and galectin-9 mRNA combination in predicting CHB with MAFLD was 0.888, much greater than 0.785 by galectin-3 mRNA or 0.791 by galectin-9 mRNA alone (P＜0.05). Conclusion PBMC galectin-3 mRNA and galectin-9 mRNA loads are abnormally increased in patients with CHB and concomitant MAFLD, and the combination of the two parameters might help predict the existence of MAFLD in patients with CHB.

Key words: Hepatitis B, Metabolism-related fatty liver disease, Galectin-3, Galectin-9, Diagnosis

刘倩, 杨洁, 张静, 宫克, 郭瑞丹. 慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 338-341.

Liu Qian, Yang Jie, Zhang Jing, et al. Implication of peripheral blood mononuclear cell galectin-3 and galectin-9 in patients with chronic hepatitis B and concomitant metabolism-related fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(3): 338-341.

参考文献

[1] 中国医师协会感染科医师分会, 国家感染性疾病临床医学研究中心. 乙型肝炎全人群管理专家共识(2023年). 中华临床感染病杂志, 2024, 17(1):1-13.
[2] 范建高,徐小元,南月敏,等.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志, 2024, 27(04):494-510.
[3] Huang XJ, Yin M, Zhou BQ, et al. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. World J Hepatol, 2023, 15(8):985-1000.
[4] Jacob R, Gorek LS. Intracellular galectin interactions in health and disease. Semin Immunopathol, 2024, 46(1-2):4.
[5] Mermutluo lu Ç, Tekin R, Tekin RC, et al. Evulation of prolidase enzyme, and galectin levels as a marker for fibrosis in patients with chronic hepatitis B. Eur Rev Med Pharmacol Sci, 2022, 26(24):9467-9472.
[6] Cyr B, Keane RW, de Rivero Vaccari JP. ASC, IL-18 and galectin-3 as biomarkers of non-alcoholic steatohepatitis: a proof of concept study. Int J Mol Sci, 2020, 21(22):8580.
[7] Chen PK, Hsu WF, Peng CY, et al. Significant association of elevated serum galectin-9 levels with the development of non-alcoholic fatty liver disease in patients with rheumatoid arthritis. Front Med (Lausanne), 2024, 2(11):1347268.
[8] Zhang P, Li H, Peng B, et al. Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis. Front Endocrinol (Lausanne), 2023, 2(14):1132085.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[10] Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7):1999-2014,e1.
[11] Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.Clin Mol Hepatol, 2023, 29(2):320-331.
[12] Durkovicova Z, Faktorova X, Jakabovicova M, et al. Molecular mechanisms in the pathogenesis of metabolically associated fatty liver disease. Bratisl Lek Listy, 2023, 124(6):427-436.
[13] Petrovic I, Pejnovic N, Ljujic B, et al. Overexpression of galectin 3 in pancreatic β cells amplifies β-cell apoptosis and islet inflammation in type-2 diabetes in mice. Front Endocrinol (Lausanne), 2020, 2(11):30.
[14] Li H, Cao Z, Wang L, et al. Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH. J Nutr Biochem, 2023, 2(112):109217.
[15] Lyu Y, Ma X, Ma Y, et al. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis, 2022, 10(6):2366-2382.
[16] Wang J, Li C, Fu J, et al.Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B. Scand J Immunol, 2019, 89(5):e12755.
[17] Okwor CIA, Oh JS, Crawley AM, et al. Expression of inhibitory receptors on T and NK cells defines immunological phenotypes of HCV patients with advanced liver fibrosis. iScience, 2020, 23(9):101513.
[18] Tang ZH, Liang S, Potter J, et al. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol, 2013, 190(4):1788-96.
[19] 王欣, 胡义扬, 刘平, 等. 高血压与非酒精性脂肪性肝病的关系. 临床肝胆病杂志, 2020, 36(11):2584-2588.
[20] Jin HL, Feng XY, Feng SL, et al. Isoquercitrin attenuates the progression of non-alcoholic steatohepatitis in mice by modulating galectin-3-mediated insulin resistance and lipid metabolism. Phytomedicine, 2024, 1(123):155188.

慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*

Implication of peripheral blood mononuclear cell galectin-3 and galectin-9 in patients with chronic hepatitis B and concomitant metabolism-related fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孔丽霞, 陈旭峰, 许艳, 周建飞, 孙舒. 恩替卡韦经治慢性乙型肝炎低病毒血症患者联合或序贯艾米替诺福韦治疗疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 334-337.
[2]	王钰, 刘洁, 樊健敏, 王成, 叶苗青. 超声声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 342-345.
[3]	卫涛涛, 刘天烨, 戴高中. 代谢相关脂肪性肝病患者回肠菌群特征研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 354-357.
[4]	董旭, 王超群, 陈怡, 朱彤, 葛玲玲, 徐爱静. 估算葡萄糖处置率评估无糖尿病人群代谢相关脂肪性肝病发生风险效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 362-365.
[5]	秦浩, 方春华, 何競, 张磊, 冉斌, 汪丽萍, 张振华. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较^*[J]. 实用肝脏病杂志, 2025, 28(3): 366-369.
[6]	马晨曦, 许静, 王艳秋. 超声声衰减系数联合血清ALT/AST比值评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 374-377.
[7]	曾艾, 王聪, 李敏, 赵伊婷, 张琴, 何梅. 剪切波弹性成像联合APRI诊断2型糖尿病合并NAFLD患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 382-385.
[8]	翟菲菲, 王彩, 王俊玲, 韩悦. 声触诊超声弹性成像联合超声半定量评分诊断慢性乙型肝炎患者早期肝硬化效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 402-405.
[9]	刘玉华, 张源, 郭家婷. 肝脏超声血流参数联合肝脾硬度检测预测乙型肝炎肝硬化并发食管静脉曲张破裂出血价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 414-417.
[10]	高建军, 张华西, 范仁宝, 王玺. CTP定量参数预测失代偿期肝硬化患者并发食管胃底静脉曲张破裂出血价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 418-421.
[11]	董彦宏, 姜琨, 黄辉, 彭钊, 程艾. MRI扫描评估原发性肝癌患者TACE术后病灶残留价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 434-437.
[12]	沙新杰, 夏晓亮. 磁共振成像增强扫描联合弥散加权成像评估良恶性肝脏肿瘤价值分析^*[J]. 实用肝脏病杂志, 2025, 28(3): 438-441.
[13]	刘倩倩, 段志娇, 陈平. 无创性评估非酒精性脂肪性肝病患者肝纤维化应用进展^*[J]. 实用肝脏病杂志, 2025, 28(3): 477-480.
[14]	陈婷婷, 丁蓉, 姬文莉, 吴梦秋. 高敏HBV DNA检测技术在低病毒血症慢性乙型肝炎患者抗病毒疗效监测中的应用^*[J]. 实用肝脏病杂志, 2025, 28(2): 178-181.
[15]	钱花, 杨忠祥, 石荔. 核苷(酸)类似物经治的慢性乙型肝炎患者发生低病毒血症影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 186-189.